Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewBropirimine
Description: Immunomodulatory and antitumor compound
Chemical Name: 2-Amino-5-bromo-6-phenyl-4(3H)-pyrimidone
Purity: ≥99% (HPLC)
Biological Activity for Bropirimine
Bropirimine is a immunomodulatory and antitumor compound. Induces interferon (IFN)-α/β production; augments natural killer (NK) cell activity. Orally active.
Technical Data for Bropirimine
| M. Wt | 266.09 |
| Formula | C10H8BrN3O |
| Storage | Desiccate at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 56741-95-8 |
| PubChem ID | 65457 |
| InChI Key | CIUUIPMOFZIWIZ-UHFFFAOYSA-N |
| Smiles | O=C1N=C(N)NC(C2=CC=CC=C2)=C1Br |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for Bropirimine
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 26.61 | 100 |
Preparing Stock Solutions for Bropirimine
The following data is based on the product molecular weight 266.09. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 3.76 mL | 18.79 mL | 37.58 mL |
| 5 mM | 0.75 mL | 3.76 mL | 7.52 mL |
| 10 mM | 0.38 mL | 1.88 mL | 3.76 mL |
| 50 mM | 0.08 mL | 0.38 mL | 0.75 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for Bropirimine
References for Bropirimine
References are publications that support the biological activity of the product.
Fujioka et al (1995) Antitumor effects of oral administration of an IF.-inducing pyrimidinone, Bropirimine, on murine renal-cell carcinoma. Cancer Chemother.Pharmacol. 36 7 PMID: 7536641
Tei et al (2002) In vitro antitumor activity of bropirimine against urinary bladder tumor cells. Anticancer Res. 22 1667 PMID: 12168852
If you know of a relevant reference for Bropirimine, please let us know.
View Related Products by Target
Keywords: Bropirimine, Bropirimine supplier, immunomodulators, immunomodulatory, antitumor, induces, interferons, ifn-a, ifn-alpha, ifn-α, ifn-b, ifn-beta, ifn-β, inducers, IFN, Cytokines, 4316, Tocris Bioscience
Citations for Bropirimine
Citations are publications that use Tocris products.
Currently there are no citations for Bropirimine. Do you know of a great paper that uses Bropirimine from Tocris? Please let us know.
Reviews for Bropirimine
Average Rating: 5 (Based on 1 Review.)
Have you used Bropirimine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Immuno-therapeutic effect of Bropirimine was studied.
By
Anonymous on 12/01/2019
Species: Human
Immuno-therapeutic effect of Bropirimine was studied against other immunomodulatory imide drugs.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.